Opportunities and challenges for the development of "core outcome sets" in neuro-oncology

Millward, Christopher P ORCID: 0000-0001-7727-1157, Armstrong, Terri S, Barrington, Heather, Brodbelt, Andrew R, Bulbeck, Helen, Byrne, Anthony, Dirven, Linda, Gamble, Carrol ORCID: 0000-0002-3021-1955, Grundy, Paul L, Islim, Abdurrahman I
et al (show 20 more authors) (2022) Opportunities and challenges for the development of "core outcome sets" in neuro-oncology. NEURO-ONCOLOGY, 24 (7). pp. 1048-1055.

Access the full-text of this item by clicking on the Open Access link.


Core Outcome Sets (COS) define minimum outcomes to be measured and reported in clinical effectiveness trials for a particular health condition/health area. Despite recognition as critical to clinical research design for other health areas, none have been developed for neuro-oncology. COS development projects should carefully consider: scope (how the COS should be used), stakeholders involved in development (including patients as both research partners and participants), and consensus methodologies used (typically a Delphi survey and consensus meeting), as well as dissemination plans. Developing COS for neuro-oncology is potentially challenging due to extensive tumor subclassification (including molecular stratification), different symptoms related to anatomical tumor location, and variation in treatment options. Development of a COS specific to tumor subtype, in a specific location, for a particular intervention may be too narrow and would be unlikely to be used. Equally, a COS that is applicable across a wider area of neuro-oncology may be too broad and therefore lack specificity. This review describes why and how a COS may be developed, and discusses challenges for their development, specific to neuro-oncology. The COS under development are briefly described, including: adult glioma, incidental/untreated meningioma, meningioma requiring intervention, and adverse events from surgical intervention for pediatric brain tumors.

Item Type: Article
Uncontrolled Keywords: core outcome set, clinical trial, effectiveness, glioma, meningioma
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 04 May 2022 10:11
Last Modified: 18 Jan 2023 21:04
DOI: 10.1093/neuonc/noac062
Open Access URL: https://doi.org/10.1093/neuonc/noac062
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3154268